Floatz Rating
B60/100
Confidence
Indicative
Sponsor
CanariaBio Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04498117CT.gov Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | CanariaBio Inc. | P3 | B · 60 |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Oregovamab | CanariaBio Inc. | P3 | CCC |
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody | M.D. Anderson Cancer Center | P2 | CCC |
| ft516 | Masonic Cancer Center, University of Minnesota | P1 | CC |
| Enoblituzumab | Masonic Cancer Center, University of Minnesota | P1 | CC |
| Cyclophosphamide | MaxCyte, Inc. | P1 | CC |
| Mcy-M11 | MaxCyte, Inc. | P1 | CC |
+1 more in the Fallopian Tube Adenocarcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IpilimumabNational Cancer Institute (NCI)CCC
- NivolumabNational Cancer Institute (NCI)CCC
- OregovamabCanariaBio Inc.CCC
- Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal AntibodyM.D. Anderson Cancer CenterCCC
- ft516Masonic Cancer Center, University of MinnesotaCC
Citation
Floatz Terminal. Carboplatin in Fallopian Tube Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-fallopian-tube-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →